# Ann-Tove Kongsnes

> Ann-Tove Kongsnes is a funding round investor at Investinor backing Biotechnology and Health Care. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Investinor](https://shizune.co/investors/profile/investinor)
- Location: Trondheim, Norway
- Total investments: 10
- Last investment: Aug 2020
- Lead investor: 80%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/ann-tove-kongsnes/3/aa9/316

Ann-Tove Kongsnes is a funding round investor at Investinor in Trondheim focused on Biotechnology and Health Care. Ann-Tove Kongsnes holds an MSc in Economics and Business Administration from Bodø College (HiB) and the Advanced Program in Corporate Finance at the Norwegian School of Economics (NHH). She was previously an investment manager at ProVenture Managment AS, Business Development Manager at Leiv Eiriksson Nyskaping AS, Director of Marketing &Operations at NSEC Inc and Marketing Manager at the Norwegian Seafood Export Council. Mrs Kongsnes is a board member of Investinor’s portfolio companies Ayanda AS, Nordic Seafarms AS, poLight AS, Pharmalink AB, Soundrop AS and Gassecure AS. She is also deputy board member at BerGenBio AS and head of International Affairs at Investinor.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 30% |
| Health Care | 2 | 20% |
| Manufacturing | 2 | 20% |
| Medical | 1 | 10% |
| Hardware | 1 | 10% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 3 | 30% |
| Series A | 2 | 20% |
| Series B | 2 | 20% |
| Series C | 1 | 10% |
| Series D | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| CardioMech | CardioMech is a developer of therapeutic devices for structural heart disease that provides a transcatheter alternative to cardiac surgery for the placement of artificial chords for the mitral valve. The company's devices are used for the placement of artificial chords, enabling surgeons to get access to new therapeutic options for heartdiseases. The technology is being developed to treat patients with severe, symptomatic, degenerative mitral regurgitation (DMR) due to prolapse or flail.CardioMech was founded in 2015 and is headquartered in Trondheim, Norway. | $18.5M | Series A | Aug 05, 2020 |  |
| Phoenix Solutions AS | Phoenix Solutions AS is a Norwegian biotech company developing a technology platform for targeted drug delivery. |  |  | Mar 01, 2017 |  |
| poLight | poLight is developing micro optics components. The technology is based on proprietary and patented methods for creating active optical components based on deformable polymers. poLight's main project is to develop the world's smallest and most cost-efficient auto focus lens for micro cameras. The poLight technology is characterized bywafer scale manufacturability, compact size, low cost and high optical quality. poLight is based in Horten, outside Oslo, Norway. | $14.9M |  | Aug 15, 2016 |  |
| BerGenBio | BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers. | $19.1M | Series D | Mar 18, 2016 |  |
| poLight | poLight is developing micro optics components. The technology is based on proprietary and patented methods for creating active optical components based on deformable polymers. poLight's main project is to develop the world's smallest and most cost-efficient auto focus lens for micro cameras. The poLight technology is characterized bywafer scale manufacturability, compact size, low cost and high optical quality. poLight is based in Horten, outside Oslo, Norway. | $19M |  | Feb 06, 2015 |  |
| BerGenBio | BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers. | $12.5M | Series C | Feb 05, 2014 |  |
| BerGenBio | BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers. | $6M | Series B | May 01, 2013 |  |
| BerGenBio | BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers. | $8.8M | Series A | Jan 09, 2012 |  |
| poLight | poLight is developing micro optics components. The technology is based on proprietary and patented methods for creating active optical components based on deformable polymers. poLight's main project is to develop the world's smallest and most cost-efficient auto focus lens for micro cameras. The poLight technology is characterized bywafer scale manufacturability, compact size, low cost and high optical quality. poLight is based in Horten, outside Oslo, Norway. | $18.5M | Series B | Jul 06, 2011 |  |
| ConCordix | ConCordix is a product of Vitux AS. Vitux is a third-party manufacturer providing private label products for the nutraceutical and dietary supplement industry. |  |  | Jul 08, 2010 |  |

10 of 10 investments shown.

## Co-investors
- [Alliance VC](https://shizune.co/investors/profile/alliance-venture) — VC Fund, 2 deals together
- [Industrifonden](https://shizune.co/investors/profile/industrifonden) — VC Fund, 2 deals together
- [Sarsia Seed Management](https://shizune.co/investors/profile/sarsia-seed-management) — VC Fund, 2 deals together
- [Aerion Partners](https://shizune.co/investors/profile/aerion-partners) — VC Fund, 1 deal together
- [Hadean Ventures](https://shizune.co/investors/profile/hadean-ventures) — VC Fund, 1 deal together
- [TD Veen](https://shizune.co/investors/profile/td-veen) — VC Fund, 1 deal together

## About Investinor

VC Fund · Trondheim, Norway

Investinor invests in Norwegian based, high potential companies that are internationally oriented and in the phases ranging from early growth to expansion. The company has BNOK 4.2 ($500 m) under management and focus on companies within the internet, software, semiconductors, energy, cleantech, marine and life sciences sectors.

5 contacts available at Investinor.

| Name | Title | Profile |
| --- | --- | --- |
| Ann-Tove Kongsnes | Investment Director | https://shizune.co/investors/profile/ann-tove-kongsnes |
| Bent Grøver | Principal | https://shizune.co/investors/profile/bent-grver |
| Birgitte Gangmark Villmo | Investment Manager | https://shizune.co/investors/profile/birgitte-gangmark-villmo |
| Egil Garberg | Investment Associate | https://shizune.co/investors/profile/egil-garberg |
| John-Arne Hørløck | Investment Associate | https://shizune.co/investors/profile/john-arne-h%C3%B8rl%C3%B8ck |

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Ann-Tove Kongsnes invest in?

Ann-Tove Kongsnes invests primarily in Biotechnology, Health Care and Manufacturing startups, most often at Funding Round and Series A stage. Most of the 10 investments tracked by Shizune back companies in Norway. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ann-Tove Kongsnes last invest?

The most recent investment recorded for Ann-Tove Kongsnes closed in Aug 2020. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co